Compare Entegris Inc (ENTG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs TransMedics Group Inc — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Entegris Inc is far larger — about 9× TransMedics Group Inc's market cap, and Entegris Inc pays a 0.25% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and TransMedics Group Inc for 24 Days on average.
| ENTG | TMDX | |
|---|---|---|
Market Cap | $24.78B | $2.74B |
Volume | 2,648,320 | 949,331 |
Sector | Technology | Health |
52-Week High | $184.00 | $150.42 |
52-Week Low | $68.80 | $61.99 |
Typical Hold Time | 41 Days | 24 Days |
Enterprise Value | $27.99B | $3.13B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $162.19, down 2.48% today but maintains strong technical momentum with bullish moving averages and key support at $158. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.93 exceeding expectations by 13%. Revenue remains stable at $3.2B annually while net margins improved to 9.18% in 2026. Recent institutional buying from BlackRock and Baird Financial Group signals confidence in the semiconductor materials supplier.
ENTG presents a compelling growth story driven by AI semiconductor demand and operational improvements, with analyst consensus targeting 12.5% upside to $182.43. However, elevated valuation multiples (P/E 81.1, EV/EBITDA 31.7) and high long-term debt of $3.98B create vulnerability to sector downturns. The stock's performance hinges on continued execution amid semiconductor cycle volatility.
TransMedics Group (TMDX) trades at $79.00, down 2.55% amid bearish technical signals and mixed earnings performance. The stock shows strong fundamentals with 58.69% gross margins and 22.69% net income margins, though profitability declined year-over-year. Recent news highlights insider buying, CFO appointment, and ongoing legal investigations into fiduciary duties, creating conflicting sentiment signals.
While analyst consensus remains bullish with a $99.75 price target, near-term risks include margin pressure from heavy investments and legal uncertainties. The stock's current valuation at 20.47 P/E offers potential upside if execution improves, but investors face volatility from earnings misses and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
